{"success":true,"data":{"pressRelease":{"id":"119289","rtpr_id":"nWkr391y27","ticker":"ELIC","exchange":"Nasdaq Stockholm","all_tickers":["ELIC"],"title":"Correction - Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date","author":"Cision","published_at":"2026-08-14T11:48:54.335Z","article_body":"Elicera Therapeutics\nGothenburg, 14 August 2026 - Elicera Therapeutics AB (publ) hereby announces a\ncorrection to the press release dated 11 August 2026 regarding the CARMA\nstudy. In the previous press release, it was incorrectly stated that tumor\nresponses were observed in all three patients who had previously been treated\nwith CAR T-cells. The correct information is that all three patients achieved\ndisease control and that two of them obtained an objective tumor response, of\nwhich one was a complete metabolic response. All other information in the\npress release dated 11 August 2026 remains unchanged. Below follows the\ncorrected press release in its entirety.\n\nThe CARMA study is a clinical Phase I/IIa trial evaluating the safety, optimal\ndosing, and preliminary efficacy of ELC-301 in patients with relapsed or\nrefractory B-cell lymphoma that have undergone at least two previous lines of\nstandard treatment with no remaining curative treatment options. The study\nincludes a dose-escalation phase (Phase I) with twelve patients across three\ncohorts to identify the maximum tolerated dose, followed by further evaluation\nof six patients in an expansion phase (Phase IIa).\n\nKey highlights from the data:\n* 11 patients have so far undergone preliminary efficacy evaluation at the\none-month follow-up.\n* No dose-limiting toxicities (DLTs) have been observed, and the treatment has\nbeen well tolerated to date. The Data Safety and Monitoring Board (DSMB) has\nnot yet assessed the third and final cohort of the Phase I part of the study.\n* Among the 11 patients treated and evaluated for preliminary efficacy to\ndate:\n * Disease control rate: 100%.\n* Overall response rate (ORR): 91% (10/11).\n* Complete metabolic response/CMR (no active disease): 55% (6/11).\n* Of the six patients with confirmed CMR at month one, four still had CMR at\ntheir most recent recorded follow-up.\n* One patient has confirmed CMR for at least 18 months. Another patient has\nconfirmed CMR for at least 12 months.\n\n* Three of the eleven evaluated patients had previously been treated with CAR\nT-cells but subsequently relapsed. After treatment with ELC-301, all three\nachieved disease control, of whom two obtained an objective tumor response,\nincluding one complete metabolic response.\n* Of the three most recently included patients in the study, one had\npreviously received CAR T treatment.\nAs soon as the twelfth and final patient in the Phase I part of the CARMA\nstudy has undergone their follow-up evaluation, the study's independent Data\nSafety and Monitoring Board (DSMB) will assess the third and final cohort. The\nDSMB's assessment will then determine the recommended Phase II dose (RP2D) to\nbe used for continued enrollment in the dose-expansion part of the study\n(Phase IIa), where an additional six patients will be treated at the maximum\ntolerated dose.\n\n\"The eleven patients evaluated so far in the CARMA study continue to show\nstrong data, with disease control in all patients and tumor responses in 91\npercent. Three of them had previously received CAR T treatment and relapsed\nand are therefore defined as particularly difficult to treat. Among the three\nmost recently included patients, one had stopped responding to their previous\nCAR T treatment - yet still achieved a tumor response with ELC-301.\nParticularly encouraging is that four of the six patients who achieved\ncomplete metabolic response remain disease-free, with one patient now\ndisease-free for at least 18 months and another for at least 12 months. This\nis an early but important indication that the responses may be durable rather\nthan temporary, which is critical for patients in this difficult-to-treat\ngroup and strengthens our confidence in the potential of ELC-301 and the iTANK\nplatform. We now look forward to completing the evaluation of the final\npatient in the Phase I study, after which the DSMB will assess the last cohort\nahead of the decision on continued enrollment in the dose-expansion part,\"\nsays Jamal El-Mosleh, CEO of Elicera Therapeutics.\n\nFor further information, please contact:\nJamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)\n\nPhone: +46 (0) 703 31 90 51\njamal.elmosleh@elicera.com\n\n\nCertified Advisor\nDNB Carnegie Investment Bank (publ) \n\nAbout the CARMA Study\nCARMA is a phase I/IIa clinical study evaluating the safety and efficacy of\nthe CAR T-cell therapy ELC-301 in the treatment of patients with B-cell\nlymphoma. The study is divided into a dose-escalation phase (phase I) and a\ndose-expansion phase (phase IIa). Phase I primarily aims to establish the\noptimal dose and safety profile in up to 12 patients, while phase IIa will\nfurther evaluate the efficacy of the maximum tolerated dose in an additional\nsix patients. Phase I is planned to include three cohorts (dosing groups),\nwith three patients in the first and second cohorts, and six patients in the\nthird cohort, who are expected to receive the maximum tolerated dose. The\nCARMA study is being conducted at Uppsala University Hospital and Karolinska\nUniversity Hospital in Huddinge.\n\n\nAbout ELC-301\nELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen,\narmed with the company’s iTANK platform to activate a broader and more\ncomprehensive parallel immune response against cancer. CAR T-cells are a form\nof cell therapy created by genetically modifying a patient’s T-cells to\nexpress a synthetic receptor (chimeric antigen receptor, CAR). This receptor\nis specifically designed to target a single tumor antigen—a molecule visible\non the surface of cancer cells—and enables the T-cells to locate, bind to,\nand destroy the cancer cells.\n\nAbout the iTANK-platform\nThe iTANK technology platform has been developed for arming and enhancing CAR\nT-cells to meet two of the major challenges CAR T-cell therapies face in the\ntreatment of solid tumors: a very diverse set of tumor antigen targets and a\nvery hostile tumor microenvironment. The technology is used to incorporate a\ntransgene into CAR T-cells encoding a neutrophil activating bacterial protein\n(NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to\nenhance the function of CAR T-cells and importantly activating a parallel\nbystander immune response against the cancer via CD8+ killer T-cells. This is\nexpected to lead to a broad attack against most antigen targets on cancer\ncells. The iTANK platform is used to enhance the company’s own CAR T-cells\nbut can also be universally applied to other CAR T-cell therapies under\ndevelopment. Proof-of-concept data was published in Nature Biomedical\nEngineering in April 2022. The publication, titled “CAR T cells expressing\na bacterial virulence factor triggers potent bystander antitumor responses in\nsolid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here:\nhttps://www.nature.com/articles/s41551-022-00875-5. More information about\niTANK platform is available here: https://www.elicera.com/technology\n\n\nAbout Elicera Therapeutics AB\nElicera Therapeutics AB (publ) has developed the patented gene technology\nplatform iTANK that enables the arming of new and existing CAR T-cell\ntherapies targeting aggressive and relapsing cancer forms. Elicera\nTherapeutics thereby addresses a well-defined and vast market. The\ncompany’s CAR T-cell therapies have shown a potent effect toward solid\ntumors which are recognized as particularly difficult to treat and constitute\nthe majority of cancer cases. The company addresses a global multibillion\nmarket in cell therapy through its offering of non-exclusive licensing of the\niTANK-platform to companies in the pharmaceutical industry. Elicera\nTherapeutics has four internal development projects in immune therapy that\nseparately have the potential to generate substantial value through exclusive\nout-licensing agreements. The company’s share is traded on Nasdaq\nFirst North Growth Market. For additional information,\nvisit www.elicera.com.\n\nhttp://publish.ne.cision.com//Release/ViewReleaseHtml/9107574C7D3F58BAE0C856B0705FC7D6\n\nPress release 260814 - Correction, CARMA update\n(https://mb.cision.com/Main/20218/4383662/4219014.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr391y27","title":"Correction - Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date","author":"Cision","ticker":"ELIC","created":"2026-08-14T11:48:54.335Z","tickers":["ELIC"],"exchange":"Nasdaq Stockholm","article_body":"Elicera Therapeutics\nGothenburg, 14 August 2026 - Elicera Therapeutics AB (publ) hereby announces a\ncorrection to the press release dated 11 August 2026 regarding the CARMA\nstudy. In the previous press release, it was incorrectly stated that tumor\nresponses were observed in all three patients who had previously been treated\nwith CAR T-cells. The correct information is that all three patients achieved\ndisease control and that two of them obtained an objective tumor response, of\nwhich one was a complete metabolic response. All other information in the\npress release dated 11 August 2026 remains unchanged. Below follows the\ncorrected press release in its entirety.\n\nThe CARMA study is a clinical Phase I/IIa trial evaluating the safety, optimal\ndosing, and preliminary efficacy of ELC-301 in patients with relapsed or\nrefractory B-cell lymphoma that have undergone at least two previous lines of\nstandard treatment with no remaining curative treatment options. The study\nincludes a dose-escalation phase (Phase I) with twelve patients across three\ncohorts to identify the maximum tolerated dose, followed by further evaluation\nof six patients in an expansion phase (Phase IIa).\n\nKey highlights from the data:\n* 11 patients have so far undergone preliminary efficacy evaluation at the\none-month follow-up.\n* No dose-limiting toxicities (DLTs) have been observed, and the treatment has\nbeen well tolerated to date. The Data Safety and Monitoring Board (DSMB) has\nnot yet assessed the third and final cohort of the Phase I part of the study.\n* Among the 11 patients treated and evaluated for preliminary efficacy to\ndate:\n * Disease control rate: 100%.\n* Overall response rate (ORR): 91% (10/11).\n* Complete metabolic response/CMR (no active disease): 55% (6/11).\n* Of the six patients with confirmed CMR at month one, four still had CMR at\ntheir most recent recorded follow-up.\n* One patient has confirmed CMR for at least 18 months. Another patient has\nconfirmed CMR for at least 12 months.\n\n* Three of the eleven evaluated patients had previously been treated with CAR\nT-cells but subsequently relapsed. After treatment with ELC-301, all three\nachieved disease control, of whom two obtained an objective tumor response,\nincluding one complete metabolic response.\n* Of the three most recently included patients in the study, one had\npreviously received CAR T treatment.\nAs soon as the twelfth and final patient in the Phase I part of the CARMA\nstudy has undergone their follow-up evaluation, the study's independent Data\nSafety and Monitoring Board (DSMB) will assess the third and final cohort. The\nDSMB's assessment will then determine the recommended Phase II dose (RP2D) to\nbe used for continued enrollment in the dose-expansion part of the study\n(Phase IIa), where an additional six patients will be treated at the maximum\ntolerated dose.\n\n\"The eleven patients evaluated so far in the CARMA study continue to show\nstrong data, with disease control in all patients and tumor responses in 91\npercent. Three of them had previously received CAR T treatment and relapsed\nand are therefore defined as particularly difficult to treat. Among the three\nmost recently included patients, one had stopped responding to their previous\nCAR T treatment - yet still achieved a tumor response with ELC-301.\nParticularly encouraging is that four of the six patients who achieved\ncomplete metabolic response remain disease-free, with one patient now\ndisease-free for at least 18 months and another for at least 12 months. This\nis an early but important indication that the responses may be durable rather\nthan temporary, which is critical for patients in this difficult-to-treat\ngroup and strengthens our confidence in the potential of ELC-301 and the iTANK\nplatform. We now look forward to completing the evaluation of the final\npatient in the Phase I study, after which the DSMB will assess the last cohort\nahead of the decision on continued enrollment in the dose-expansion part,\"\nsays Jamal El-Mosleh, CEO of Elicera Therapeutics.\n\nFor further information, please contact:\nJamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)\n\nPhone: +46 (0) 703 31 90 51\njamal.elmosleh@elicera.com\n\n\nCertified Advisor\nDNB Carnegie Investment Bank (publ) \n\nAbout the CARMA Study\nCARMA is a phase I/IIa clinical study evaluating the safety and efficacy of\nthe CAR T-cell therapy ELC-301 in the treatment of patients with B-cell\nlymphoma. The study is divided into a dose-escalation phase (phase I) and a\ndose-expansion phase (phase IIa). Phase I primarily aims to establish the\noptimal dose and safety profile in up to 12 patients, while phase IIa will\nfurther evaluate the efficacy of the maximum tolerated dose in an additional\nsix patients. Phase I is planned to include three cohorts (dosing groups),\nwith three patients in the first and second cohorts, and six patients in the\nthird cohort, who are expected to receive the maximum tolerated dose. The\nCARMA study is being conducted at Uppsala University Hospital and Karolinska\nUniversity Hospital in Huddinge.\n\n\nAbout ELC-301\nELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen,\narmed with the company’s iTANK platform to activate a broader and more\ncomprehensive parallel immune response against cancer. CAR T-cells are a form\nof cell therapy created by genetically modifying a patient’s T-cells to\nexpress a synthetic receptor (chimeric antigen receptor, CAR). This receptor\nis specifically designed to target a single tumor antigen—a molecule visible\non the surface of cancer cells—and enables the T-cells to locate, bind to,\nand destroy the cancer cells.\n\nAbout the iTANK-platform\nThe iTANK technology platform has been developed for arming and enhancing CAR\nT-cells to meet two of the major challenges CAR T-cell therapies face in the\ntreatment of solid tumors: a very diverse set of tumor antigen targets and a\nvery hostile tumor microenvironment. The technology is used to incorporate a\ntransgene into CAR T-cells encoding a neutrophil activating bacterial protein\n(NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to\nenhance the function of CAR T-cells and importantly activating a parallel\nbystander immune response against the cancer via CD8+ killer T-cells. This is\nexpected to lead to a broad attack against most antigen targets on cancer\ncells. The iTANK platform is used to enhance the company’s own CAR T-cells\nbut can also be universally applied to other CAR T-cell therapies under\ndevelopment. Proof-of-concept data was published in Nature Biomedical\nEngineering in April 2022. The publication, titled “CAR T cells expressing\na bacterial virulence factor triggers potent bystander antitumor responses in\nsolid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here:\nhttps://www.nature.com/articles/s41551-022-00875-5. More information about\niTANK platform is available here: https://www.elicera.com/technology\n\n\nAbout Elicera Therapeutics AB\nElicera Therapeutics AB (publ) has developed the patented gene technology\nplatform iTANK that enables the arming of new and existing CAR T-cell\ntherapies targeting aggressive and relapsing cancer forms. Elicera\nTherapeutics thereby addresses a well-defined and vast market. The\ncompany’s CAR T-cell therapies have shown a potent effect toward solid\ntumors which are recognized as particularly difficult to treat and constitute\nthe majority of cancer cases. The company addresses a global multibillion\nmarket in cell therapy through its offering of non-exclusive licensing of the\niTANK-platform to companies in the pharmaceutical industry. Elicera\nTherapeutics has four internal development projects in immune therapy that\nseparately have the potential to generate substantial value through exclusive\nout-licensing agreements. The company’s share is traded on Nasdaq\nFirst North Growth Market. For additional information,\nvisit www.elicera.com.\n\nhttp://publish.ne.cision.com//Release/ViewReleaseHtml/9107574C7D3F58BAE0C856B0705FC7D6\n\nPress release 260814 - Correction, CARMA update\n(https://mb.cision.com/Main/20218/4383662/4219014.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-08-14T11:48:54.424220835Z","server_sent_at_ms":1786708134424},"received_at":"2026-08-14T11:48:54.476Z","source_url":null},"analysis":{"id":"108277","press_release_id":"119289","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Correction issued to prior press release correcting response rate details in CAR-T pre-treated subgroup"],"eventType":"clinical_trial","narrative":"Elicera Therapeutics reported updated efficacy data from the Phase I portion of the CARMA study evaluating ELC-301, showing a 91% overall response rate and 100% disease control rate across 11 evaluated patients.\n\nThe company issued a correction to a previous release, clarifying that while all three patients previously treated with CAR T-cells achieved disease control, two obtained an objective tumor response rather than all three as initially stated.\n\nNo dose-limiting toxicities have been observed to date, and the Data Safety Monitoring Board will assess the final cohort to determine the recommended Phase II dose.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"High response rates in difficult-to-treat lymphoma patients support potential of iTANK-enabled ELC-301."},"keyFigures":{"drugName":"ELC-301","phaseOfTrial":"Phase I","customDimensions":{"cmr":"55%","dcr":"100%","orr":"91%","patients_evaluated":11,"durable_cmr_12_months_plus":2}},"quotedText":"The eleven patients evaluated so far in the CARMA study continue to show strong data, with disease control in all patients and tumor responses in 91 percent.","namedEntities":{"people":[{"name":"Jamal El-Mosleh","role":"CEO"}],"products":["ELC-301","iTANK"],"companies":[{"name":"Elicera Therapeutics AB","ticker":"ELIC"},{"name":"DNB Carnegie Investment Bank","relationship":"Certified Advisor"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Strong preliminary efficacy data from the Phase I CARMA study shows a 91% overall response rate and 100% disease control rate in a difficult-to-treat population with no observed dose-limiting toxicities. Although the release corrects a prior overstatement regarding efficacy in pre-treated CAR-T patients, the aggregate data remains highly positive for a clinical-stage asset."},"tickerRelevance":{"others":[],"primary":"ELIC"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"strong_phase_i_data","correctionImpact":"minor"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Elicera Therapeutics reported updated efficacy data from the Phase I portion of the CARMA study evaluating ELC-301, showing a 91% overall response rate and 100% disease control rate across 11 evaluated patients.\n\nThe company issued a correction to a previous release, clarifying that while all three patients previously treated with CAR T-cells achieved disease control, two obtained an objective tumor response rather than all three as initially stated.\n\nNo dose-limiting toxicities have been observed to date, and the Data Safety Monitoring Board will assess the final cohort to determine the recommended Phase II dose.","key_figures":{"drugName":"ELC-301","phaseOfTrial":"Phase I","customDimensions":{"cmr":"55%","dcr":"100%","orr":"91%","patients_evaluated":11,"durable_cmr_12_months_plus":2}},"named_entities":{"people":[{"name":"Jamal El-Mosleh","role":"CEO"}],"products":["ELC-301","iTANK"],"companies":[{"name":"Elicera Therapeutics AB","ticker":"ELIC"},{"name":"DNB Carnegie Investment Bank","relationship":"Certified Advisor"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-14T12:19:40.782Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"strong_phase_i_data","correctionImpact":"minor"}},"durationMs":132803,"modelName":"glm-4.7"}}